Chris Ryan

In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.

Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.

A look at the top multiple myeloma abstracts set to be presented at the 2025 ASH Annual Meeting.

Silevertinib produced responses in NSCLC harboring non-classical EGFR mutations and will also be investigated in newly diagnosed glioblastoma.

The prescribing information for cosibelimab in advanced cutaneous squamous cell carcinoma was updated to include long-term data from the CK-301-101 trial.

The FDA approved durvalumab plus FLOT for the perioperative treatment of resectable gastric and gastroesophageal junction cancers.

Joshua Richter, MD, discusses the evaluation of the FcRH5 x CD3 bispecific antibody in multiple myeloma.

Subcutaneous toripalimab generated non-inferior efficacy and safety outcomes vs the IV formulation in recurrent/metastatic non squamous NSCLC.

The FDA granted fast track designation to AVZO-103 for urothelial cancer previously treated with enfortumab vedotin.

Shubham Pant, MD, MBBS, explores frontline chemotherapy decision-making in metastatic pancreatic cancer.

Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.

HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.

Vorasidenib plus temozolomide was safe in glioma harboring IDH1/2 mutations.

The FDA has approved neoadjuvant/adjuvant enfortumab vedotin plus pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer.

Will the FDA approve zidesamtinib for ROS1-positive advanced non–small cell lung cancer after a prior TKI?

Joshua Richter, MD, discusses the exploration of CELMoDs in the treatment of patients with multiple myeloma.

The FDA approved selumetinib for the treatment of adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

The FDA granted fast track designation to FOG-001 for the treatment of patients with desmoid tumors.

The FDA granted 510(k) clearance to the EXENT System to aid in the diagnosis of multiple myeloma and related disorders.

The FDA granted RMAT designation to MB-105 for CD5-positive relapsed/refractory T-cell lymphoma.

The FDA granted orphan drug designation to tinostamustine for malignant glioma.

Nivolumab with or without relatlimab exceeded historical benchmarks in TLS-positive soft tissue sarcoma, validating TLS as a predictive biomarker.

The FDA has approved generic dasatinib tablets for select patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Marlana Orloff, MD, discusses data for the combination of darovasertib and crizotinib in metastatic uveal melanoma.

The FDA has approved daratumumab and hyaluronidase-fihj for the treatment of adult patients with high-risk smoldering multiple myeloma.

GFH375 produced responses and tumor shrinkage in heavily pretreated pancreatic ductal adenocarcinoma harboring KRAS G12D mutations.

Treatment with 177Lu-edotreotide was linked to improvements in PFS and ORR across subgroups of patients with SSTR-positive GEP-NETs.

HER2DX low-risk scores were associated with improved 10-year RFS and OS outcomes in older patients with HER2-positive early-stage breast cancer.

The FDA has added REMS guidelines for the use of pexidartinib in tenosynovial giant cell tumor.

CB-011 elicited responses in patients with relapsed/refractory multiple myeloma.